Change in Preferred Drug List Status for Antihyperuricemics Drug Class

Date: April 25, 2024

Attention: All Providers

Effective date: April 22, 2024

Call to action: Effective April 22, 2024, the Texas Health and Human Services (HHS) removed non-preferred status from brand name Mitigare products. This is in response to the discontinuation of the brand products Colcrys by the manufacturer.

The preferred status of the brand name Colcrys will not change to allow any remaining stock to be used.

How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.

Please see below for the list of impacted drugs (of note, the approval is NDC-specific):

Preferred Medication NDC	Preferred Medication	Type of Change	Effective Date
59467031801	MITIGARE 0.6 MG CAPSULE	Brand now preferred	April 22,2024
59467031810	MITIGARE 0.6 MG CAPSULE	Brand now preferred	April 22,2024
59467031830	MITIGARE 0.6 MG CAPSULE	Brand now preferred	April 22,2024

Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.

For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.